Abstract 15353: Recombinant Human Growth Hormone Diminishes Cell Injury, Remodeling and Ventricular Dysfunction in Dilated Cardiomyopathy in Young Rat
Background and Objectives: Although there is conflicting evidence in the beneficial effects of recombinant human growth hormone (rhGH) for dilated cardiomyopathy (DCM) in adults, data suggest that it may be efficacious for DCM in children. We sought to test the hypothesis that rhGH restores the GH/insulin-like growth factor-1 (IGF-1) axis and facilitates cell growth, repair, and functional and hemodynamic improvement for DCM in the young.
Methods: A total of 60 two-week old SD rats were randomized into 3 groups. DCM was induced by Furazolidone (0.25 mg/g) administered gastrically in Group 1 (Treatment: rhGH: 0.15u/kg IP QD) and Group 2 (Placebo: Normal Saline IP QD), and compared with Group 3 (Control). Twelve weeks after the treatment, echocardiography, cardiac catheterization, serum markers, and postmortem histopathology were obtained for analysis.
Results: Following treatment, the body weight, IGF-1, and IGF binding protein-3 (IGFBP-3) increased in Group 1 than Group 2 and 3. Cardiac troponin I and T and N-terminal pro-brain natriuretic peptide decreased in Group 1 than Group 2. Left ventricular (LV) cavity sizes decreased but wall thickness, fractional shortening (FS) and ejection fraction (EF) increased in Group 1 than Group 2 by echocardiography (FS: Group 1: 45.7±8.2% vs Group 2: 37.0±8.5% vs Group 3: 51.5±7.3%, P<0.0001, and EF: Group 1: 79.1±15.4% vs Group 2: 48.2±13.2% vs Group 3: 85.4±14.3%, P<0.0001). Furthermore, central venous pressure, LV end diastolic pressure and heart rate were lower in Group 1 than Group 2. Histopathology showed cell injury, fibrosis, and remodeling in Group 2, which were significantly less in Group 1.
Conclusions: Our study suggests that rhGH augments GH/IGF axis, diminishes cell injury, fibrosis, and remodeling, therefore, improves LV size, wall thickness, systolic function and hemodynamics in young rats with DCM. Further investigation and clinical trial is warranted to validate the efficacy of this therapy for DCM in children.
- © 2013 by American Heart Association, Inc.